• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Welldoc, Dexcom expand diabetes management tech partnership

April 5, 2021 By Sean Whooley

Welldoc DexcomWelldoc announced today that it will offer its BlueStar digital health solution with Dexcom’s G6 CGM system as a single platform.

Columbia, Md.-based Welldoc’s FDA-cleared BlueStar system offers guidance to individuals through the self-management of diabetes, while Dexcom’s G6 continuous glucose monitoring (CGM) system measures glucose levels just beneath the skin’s surface and wirelessly transmits data every five minutes.

G6 is a slim, water-resistant FDA-cleared CGM that offers an alternative to traditional fingersticks, while its customizable alarms alert users of dangerous glucose levels.

The combined platform with G6 and BlueStar can offer tailored, real-time feedback, connectivity options, seamless integration, data aggregation and remote patient monitoring codes for reimbursement, according to a news release.

“This partnership allows us to bring together the two most challenging, and often independent, elements of diabetes management – glucose monitoring and the impact of lifestyle choices – for the first time. Through a new app experience, users will be able to manage multiple facets of their health while also improving data sharing with their care team,” Welldoc CEO Kevin McRaith said in the release. “Our goal at Welldoc is to advance the self-management of chronic conditions, improve population health and reduce costs. Our integrated offering with Dexcom is an important advancement in these efforts.”

“During the pandemic, we have observed the value of Dexcom CGM for all people with diabetes. By integrating CGM with engaging digital health solutions, we have simplified and improved management for people living with Type 2 diabetes,” added Dexcom SVP of strategy, corporate development & new markets Matt Dolan. “Our expanded partnership with Welldoc will empower users to take control of their health by combining real-time CGM data and AI-driven digital health coaching.”

Welldoc entered into a similar partnership with Eli Lilly in February to integrate its software into Lilly’s connected insulin pens, which are in development.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Pharmaceuticals Tagged With: Dexcom, welldoc

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS